Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 19

Results For "NEC"

1348 News Found

G42 Healthcare, Abu Dhabi and AstraZeneca to collaborate on clinical research
Biotech | December 29, 2021

G42 Healthcare, Abu Dhabi and AstraZeneca to collaborate on clinical research

G42 Healthcare and AstraZeneca will work closely together to explore real-world evidence and conduct clinical trials through IROS – the first-of-its-kind Contract Research Organization (CRO) in the UAE


Study shows AstraZeneca’s Covid-19 booster dose protects against Omicron
News | December 23, 2021

Study shows AstraZeneca’s Covid-19 booster dose protects against Omicron

Neutralising antibody levels against Omicron following a third dose boost of Vaxzevria were broadly similar to levels achieved after two doses against the Delta variant


Astra Zeneca’s antibody combination to prevent Covid-19 neutralises Omicron variant
News | December 17, 2021

Astra Zeneca’s antibody combination to prevent Covid-19 neutralises Omicron variant

The study was performed independently by investigators at the US Food and Drug Administration (FDA), Center for Biologics Evaluation and Research


Samsung Biologics expands tie-up with AstraZeneca to include cancer therapy
Biotech | December 14, 2021

Samsung Biologics expands tie-up with AstraZeneca to include cancer therapy

The company will manufacture a cancer immunotherapy product from 2022


AstraZeneca opens Discovery Centre in Cambridge
Biotech | November 23, 2021

AstraZeneca opens Discovery Centre in Cambridge

State-of-the-art R&D facility designed to foster collaboration across world-class science ecosystem


AstraZeneca’s Covid-19 drug offers 83% protection over six months
Biotech | November 18, 2021

AstraZeneca’s Covid-19 drug offers 83% protection over six months

Six-months follow-up of prevention trial showed 83% reduced risk of symptomatic Covid-19, with no severe disease or deaths


AstraZeneca Pharma India PAT at Rs 11.94 cr. in Q2FY22
News | November 10, 2021

AstraZeneca Pharma India PAT at Rs 11.94 cr. in Q2FY22

The Board of Directors of AstraZeneca Pharma India have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021


AstraZeneca to transfer global rights for Eklira and Duaklir to Covis Pharma
Biotech | November 02, 2021

AstraZeneca to transfer global rights for Eklira and Duaklir to Covis Pharma

The agreement sharpens the company’s focus on priority medicines in respiratory & immunology portfolio


Solve.Care and AliveCor partner to connect KardiaMobile users with physicians
Digitisation | October 29, 2021

Solve.Care and AliveCor partner to connect KardiaMobile users with physicians

The collaboration provides KardiaMobile users quick access to doctors worldwide for consultations about their ECG readings


AstraZeneca partners with India-Sweden Healthcare Innovation Centre and AIIMS to upskill nurses
Public Health | October 28, 2021

AstraZeneca partners with India-Sweden Healthcare Innovation Centre and AIIMS to upskill nurses

This capability programme aims to upskill 5000 nurses across the country in the next year by converting the current modules into an e-learning one